arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Harmony Biosciences Holdings, Inc.

HRMY
$40.52 ▼ -1.02 (-2.46%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
30 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
84
Health
Excellent
Bullish
auto_awesome

Analytical Summary

Harmony Biosciences Holdings, Inc. shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $2.3B
Dividend Yield —
Revenue Growth 30.3% ↗
Op. Margin 34.2% ↗
ROIC 6.3% ↗
FCF / Share $1.60 ↗
Trailing P/E 31.2x
Price / Book 2.4x
FCF Yield 3.9%
Debt / Equity 0.15
info Valuation on last close. End-of-day price, Sep 23, 2026.

30-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$261.28M
↑ +30.3% —
Net Income Profit after all expenses
$75.43M
↑ +89.6% —
Operating Margin Operating profit as % of sales
34.2%
↑ +97.4% 80th
FCF / Share Free cash flow per share
$1.60
↑ +232.3% —
Long-Term Debt Long-term obligations
$153.96M
↓ -3.1% —
trending_up

Bullish Indicators

  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability ↑
85
Returns →
84
Financial Health →
79
Cash Quality ↓
88

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 8 years · 30 quarters